MiMedx Group, Inc. (NASDAQ:MDXG – Get Rating) insider Robert Benjamin Stein sold 19,000 shares of MiMedx Group stock in a transaction on Monday, September 12th. The shares were sold at an average price of $3.44, for a total transaction of $65,360.00. Following the completion of the sale, the insider now directly owns 287,002 shares of the company's stock, valued at $987,286.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Robert Benjamin Stein also recently made the following trade(s):
Get MiMedx Group alerts:- On Friday, August 12th, Robert Benjamin Stein sold 8,503 shares of MiMedx Group stock. The shares were sold at an average price of $4.04, for a total transaction of $34,352.12.
- On Thursday, August 4th, Robert Benjamin Stein sold 19,500 shares of MiMedx Group stock. The shares were sold at an average price of $3.62, for a total transaction of $70,590.00.
- On Tuesday, June 28th, Robert Benjamin Stein sold 14,600 shares of MiMedx Group stock. The shares were sold at an average price of $3.47, for a total transaction of $50,662.00.
MiMedx Group Price Performance
Shares of NASDAQ MDXG remained flat at $3.46 during mid-day trading on Wednesday. 755,400 shares of the stock were exchanged, compared to its average volume of 536,099. The company has a market capitalization of $393.09 million, a PE ratio of -13.84 and a beta of 1.75. The business has a fifty day moving average of $3.68 and a 200-day moving average of $3.98. MiMedx Group, Inc. has a 52-week low of $3.04 and a 52-week high of $8.69. The company has a debt-to-equity ratio of 586.91, a quick ratio of 3.17 and a current ratio of 3.53.
MiMedx Group (NASDAQ:MDXG – Get Rating) last released its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The company had revenue of $66.88 million for the quarter, compared to analyst estimates of $65.07 million. Equities research analysts anticipate that MiMedx Group, Inc. will post -0.29 earnings per share for the current fiscal year.Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd purchased a new position in MiMedx Group during the fourth quarter worth about $41,000. Russell Investments Group Ltd. purchased a new position in MiMedx Group during the second quarter worth about $28,000. Spinnaker Investment Group LLC purchased a new position in MiMedx Group during the fourth quarter worth about $47,000. Tiedemann Advisors LLC purchased a new position in MiMedx Group during the first quarter worth about $49,000. Finally, E Fund Management Co. Ltd. purchased a new position in MiMedx Group during the first quarter worth about $50,000. 60.86% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages have recently issued reports on MDXG. HC Wainwright reduced their price objective on shares of MiMedx Group from $8.50 to $8.00 and set a "buy" rating for the company in a report on Wednesday, September 7th. StockNews.com cut shares of MiMedx Group from a "buy" rating to a "hold" rating in a report on Friday, September 9th.
About MiMedx Group
(Get Rating)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Further Reading
- Get a free copy of the StockNews.com research report on MiMedx Group (MDXG)
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- Four Cheap Stocks With Interesting Insider Activity
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- It's Time To Embrace Another 25% Decline In The S&P 500
- Is Five Below Trying to Punch Too High?
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.